Pancreatic Cancer Research

ResearcherQueen Mary University of LondonActive in the last 2 years

Yaohe Wang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-2367-6313; OpenAlex author ID A5079279782, A5081271163. Sources: OpenAlex.

Their work

Papers
19 (first author 0, last author 10)
Trials
0
Grants
0
Labs led
1
Collaborators
31
Papers, trials and grants by year

2015: 3 papers · 2016: none · 2017: 1 paper · 2018: none · 2019: none · 2020: 3 papers · 2021: 2 papers · 2022: 1 paper · 2023: none · 2024: 2 papers · 2025: 5 papers · 2026: 2 papers

Papers 19

  1. Correction to "Mapping Tumor-Stroma-ECM Interactions in Spatially Advanced 3D Models of Pancreatic Cancer". Co-author DOI 10.1021/acsami.6c14723↗
  2. IL-23-engineered oncolytic vaccinia virus enhances pancreatic cancer control through inflammasome-driven Th17-skewed CD4+ T-cell responses. Co-author DOI 10.1136/jitc-2026-016326↗
  3. Mapping Tumor-Stroma-ECM Interactions in Spatially Advanced 3D Models of Pancreatic Cancer. Co-author DOI 10.1021/acsami.5c02296↗
  4. Novel oncolytic vaccinia virus armed with interleukin-27 is a potential therapeutic agent for the treatment of murine pancreatic cancer. Last author DOI 10.1136/jitc-2024-010341↗
  5. Oncolytic Vaccinia Virus Armed with GM-CSF and IL-7 Enhances Antitumor Immunity in Pancreatic Cancer. Co-author DOI 10.3390/biomedicines13040882↗
  6. Correction: Yan et al. Oncolytic Vaccinia Virus Armed with GM-CSF and IL-7 Enhances Antitumor Immunity in Pancreatic Cancer. Biomedicines 2025, 13, 882. Co-author DOI 10.3390/biomedicines13082011↗
  7. The Combination of Oncolytic Virus and Antibody Blockade of TGF-β Enhances the Efficacy of αvβ6-Targeting CAR T Cells Against Pancreatic Cancer in an Immunocom… Co-author DOI 10.3390/cancers17091534↗
  8. GM-CSF and IL-21-armed oncolytic vaccinia virus significantly enhances anti-tumor activity and synergizes with anti-PD1 immunotherapy in pancreatic cancer. Co-author DOI 10.3389/fimmu.2024.1506632↗
  9. Inhibition of Bromodomain Proteins Enhances Oncolytic HAdVC5 Replication and Efficacy in Pancreatic Ductal Adenocarcinoma (PDAC) Models. Co-author DOI 10.3390/ijms25021265↗
  10. MHC class II molecules on pancreatic cancer cells indicate a potential for neo-antigen-based immunotherapy. Last author DOI 10.1080/2162402x.2022.2080329↗
  11. A systemically deliverable Vaccinia virus with increased capacity for intertumoral and intratumoral spread effectively treats pancreatic cancer. Last author DOI 10.1136/jitc-2020-001624↗
  12. Correction: A Virus-infected, Reprogrammed Somatic Cell-derived Tumor Cell (VIReST) Vaccination Regime can Prevent Initiation and Progression of Pancreatic Can… Last author DOI 10.1158/1078-0432.ccr-21-0850↗
  13. Pancreatic Cancer UK Grand Challenge: Developments and challenges for effective CAR T cell therapy for pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.pan.2020.02.006↗
  14. A Virus-Infected, Reprogrammed Somatic Cell-Derived Tumor Cell (VIReST) Vaccination Regime Can Prevent Initiation and Progression of Pancreatic Cancer. Last author DOI 10.1158/1078-0432.ccr-19-1395↗
  15. Promising xenograft animal model recapitulating the features of human pancreatic cancer. Last author DOI 10.3748/wjg.v26.i32.4802↗
  16. Genomic Variations in Pancreatic Cancer and Potential Opportunities for Development of New Approaches for Diagnosis and Treatment. Last author DOI 10.3390/ijms18061201↗
  17. New role of Interleukin-10 in enhancing the antitumor efficacy of oncolytic vaccinia virus for treatment of pancreatic cancer. Last author DOI 10.1080/2162402x.2015.1038689↗
  18. A vaccinia virus armed with interleukin-10 is a promising therapeutic agent for treatment of murine pancreatic cancer. Last author DOI 10.1158/1078-0432.ccr-14-0464↗
  19. Vaccinia virus, a promising new therapeutic agent for pancreatic cancer. Last author DOI 10.2217/imt.15.90↗

Closest collaborators

The 25 strongest of 31 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Louisa S. Chard · 9 shared papers, 2015–2025 · strength 1.14
  2. Wenyi Yan · 5 shared papers, 2024–2026 · strength 1.10
  3. Pengju Wang · 4 shared papers, 2025–2026 · strength 0.91
  4. Yujing Xuan · 4 shared papers, 2024–2026 · strength 0.88
  5. Lingling Si · 4 shared papers, 2024–2026 · strength 0.88
  6. Hemant Mahendrakumar Kocher · 3 shared papers, 2022–2026 · strength 0.73
  7. Anna-Dimitra Kataki · 2 shared papers, 2025–2026 · strength 0.58
  8. Priyanka Gupta · 2 shared papers, 2025–2026 · strength 0.58
  9. Pedro Antonio Pérez-Mancera · 2 shared papers, 2025–2026 · strength 0.58
  10. Eirini G. Velliou · 2 shared papers, 2025–2026 · strength 0.58
  11. Renato B. Baleeiro · 2 shared papers, 2022–2025 · strength 0.40
  12. Lauren C. Cutmore · 2 shared papers, 2020–2025 · strength 0.37
  13. Nicholas Fraser Brown · 2 shared papers, 2020–2025 · strength 0.37
  14. John F. Marshall · 2 shared papers, 2020–2025 · strength 0.37
  15. Claude Chelala · 3 shared papers, 2020–2022 · strength 0.32
  16. Shuangshuang Lu · 3 shared papers, 2017–2021 · strength 0.27
  17. Zuoyi Zhao · 1 shared paper, 2025 · strength 0.26
  18. Yu Guo · 1 shared paper, 2026 · strength 0.25
  19. Pengju Wang · 2 shared papers, 2015–2024 · strength 0.23
  20. Jinxin Miao · 2 shared papers, 2020–2021 · strength 0.23
  21. Yangyang Jia · 1 shared paper, 2025 · strength 0.22
  22. Tizong Miao · 1 shared paper, 2024 · strength 0.22
  23. Gunnel Halldén · 1 shared paper, 2024 · strength 0.22
  24. Jun Wang · 2 shared papers, 2020–2021 · strength 0.17
  25. Giulia Marelli · 1 shared paper, 2021 · strength 0.12

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.